Tag:
Celsion
Latest Headlines
Latest Headlines
Celsion shares routed after PhIII liver cancer study flops
Celsion was the center of a considerable amount of market buzz over the last year as the small biotech pushed a late-stage cancer drug through a Phase III liver cancer study. Its stock price tripled as investors rode a swell of enthusiasm that Celsion could beat the tough odds that face any small-cap company trying to make it all the way through an oncology program.
Celsion snags up to $100M Chinese pharma tie-up ahead of PhIII cancer data
Celsion ($CLSN) grabbed $5 million in a development deal with China's Zhejiang Hisun Pharmaceutical, which has shown interest in advancing Celsion's ThermoDox product in China, Hong Kong and Macau.
ThermoDox a step away from orphan approval in Europe
Celsion ( $CLSN ), a drug-development company based in Columbia, MD, has announced that the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency has issued a positive opinion
Heat-activated liposomes attracts SBIR grant
Celsion, a drug-development company based in Columbia, MD, has been awarded a $200,000 Phase I SBIR grant from the NIH for its low heat-activated liposomes, which the company says enables delivery of
Celsion's ThermoDox liver cancer trials get fast-tracked
Drug developer Celsion and sufferers of primary liver cancer received some good news from the FDA this week as the Columbia, MD-based company's first drug, ThermoDox, was granted fast-track status.
